Patent ID: 9550818
Date: 2017-01-24
CPC Classifications: A61K,C07K

Claim:
1. A method for treating a disease characterized by pathological angiogenesis, comprising administering to a patient in need thereof a pharmaceutically effective amount of a vascular endothelial cell growth factor (VEGF) variant polypeptide having the ability to antagonize VEGF mediated angiogenesis and comprising (1) a polypeptide comprising a polypeptide selected from the group consisting of SEQ ID NO:25 wherein the amino acid at positions 149, 150, and 185 of SEQ NO:25 is glutamic acid or aspartic acid, SEQ ID NO:26 wherein the amino acid at positions 123, 124, and 159 of SEQ ID NO:26 is glutamic acid or aspartic acid, or (2) a polypeptide comprising a polypeptide having at least 95% identity to a polypeptide of (1) and having the identified amino acid substitutions of (1).